ID   S_N40R2
AC   CVCL_HG10
DR   ECACC; 17011210
DR   Wikidata; Q54951556
DR   Ximbio; 152838
RX   PubMed=27323823;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Derived from sampling site: Bone; femur.
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 7.3,10.1
ST   D13S317: 12
ST   D16S539: 9,10
ST   D18S51: 15,17
ST   D21S11: 28,33.2
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 22,23
ST   Penta D: 2.2,10
ST   Penta E: 11,14
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 19
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1697 ! SJSA-1
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 16-12-21; Version: 10
//
RX   PubMed=27323823; DOI=10.18632/oncotarget.10073;
RA   Drummond C.J., Esfandiari A., Liu J., Lu X., Hutton C., Jackson J.,
RA   Bennaceur K., Xu Q., Makimanejavali A.R., Del Bello F.,
RA   Piergentili A., Newell D.R., Hardcastle I.R., Griffin R.J., Lunec J.;
RT   "TP53 mutant MDM2-amplified cell lines selected for resistance to
RT   MDM2-p53 binding antagonists retain sensitivity to ionizing
RT   radiation.";
RL   Oncotarget 7:46203-46218(2016).
//